Dr. James Brewer on NeuroQuant

DrJamesBrewer.jpgDr. Brewer is the Chief Medical Advisor for Cortechs.ai and was the first physician to incorporate NeuroQuant® into clinical practice. He assisted in the design of the NeuroQuant reports and in the studies that led to NeuroQuant’s FDA clearance in 2006.

In 2004, he joined the faculty of the University of California, San Diego, where he has a joint appointment in Radiology and Neurosciences. Dr. Brewer sees patients at the University of California, San Diego and the Veterans Affairs Hospital in La Jolla.

Dr. Brewer’s primary research interest is human memory. He uses functional and structural magnetic resonance imaging (MRI) to study memory processes in volunteers with healthy memory and in patients with memory impairment, such as cases caused by Alzheimer’s disease (AD).

Dr. Brewer received his graduate and medical training at Stanford University and his neurology residency training at Johns Hopkins University.

In the webinar below, Dr. Brewer shares his experience using NeuroQuant, and gives an overview how NeuroQuant can help physicians improve their assessment of neurodegenerative disease, such as Alzheimer’s disease, multiple sclerosis, epilepsy, as well brain trauma and brain development.

More Resources

10/10/2026

World Mental Health Day: Why Brain Health and Mental Health Belong Together

Behind every brain scan is a person. Here’s why their voice matters.

09/30/2026

Today’s Examination Becomes Tomorrow’s Baseline: The Benefits of Performing Quantitative Analysis on Every Brain MRI

A single brain MRI shows where a patient is today. A quantitative baseline can help show how the brain changes over time.

09/18/2026

What a Head CT Can and Can’t Tell You About a Concussion

For Concussion Awareness Day, learn how quantitative CT analysis can help measure subtle structural changes and support follow-up after traumatic brain injury.

09/09/2026

Prostate Cancer Awareness Month: Finding the Cancer That Matters

How quantitative MRI can bring greater clarity to decisions across the prostate cancer journey.

09/01/2026

Quantifying What Matters: Advancing Alzheimer’s Imaging with NeuroQuant®

Explore how quantitative imaging is transforming Alzheimer’s care, from structural volumetrics and amyloid PET to treatment monitoring with NeuroQuant®.

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.
Scroll to Top